MedTrace Logo

The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy

NCT04765124 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2021-06-07

No results posted yet for this study

Summary

This study is a Non-Interventional Study (NIS) with secondary data usage. It is designed as a multi-center retrospective cohort study in which the data of adult locally advanced HER2-positive breast cancer patients, who are treated with as neoadjuvant therapy, who underwent breast surgery in participating centers, were taken from hospital records.

The source population is academic or community oncology centers treating patients with breast cancer from Turkey.

The study population is planned to be the subgroup of breast cancer patients, who are treated with trastuzumab plus taxane with or without pertuzumab as neoadjuvant therapy, and underwent breast surgery at the participating centers.

The study is anticipated to include approximately 1500 patients from 20 sites.

Conditions

Sponsors & Collaborators

  • Medipol University

    collaborator OTHER

  • Bezmialem Vakif University

    collaborator OTHER

  • Koç University

    collaborator OTHER

  • Medical Park AG

    collaborator INDUSTRY

  • Uludag University

    collaborator OTHER

  • Akdeniz University

    collaborator OTHER

  • Dicle University

    collaborator OTHER

  • Trakya University

    collaborator OTHER

  • Ankara City Hospital Bilkent

    collaborator OTHER

  • Memorial Ankara Hospital

    collaborator OTHER

  • Gulhane Training and Research Hospital

    collaborator OTHER_GOV

  • Liv Hospital Ankara

    collaborator OTHER

  • Ankara University

    collaborator OTHER

  • Istanbul Medeniyet University

    collaborator OTHER

  • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

    collaborator OTHER

  • Acıbadem Atunizade Hospital

    collaborator OTHER

  • Inonu University

    collaborator OTHER

  • Ege University

    collaborator OTHER

  • Ahmet Bilici

    lead OTHER

Principal Investigators

  • Ahmet Bilici, Prof · Medipol University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2021-11-15
Completion
2021-11-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04765124 on ClinicalTrials.gov